Controlled release technology: complete guide to modified release pharmaceuticals
What is controlled release?
Controlled release (CR) is a pharmaceutical formulation strategy in which the active substance is not released immediately after intake, but dosed over time or at a specific location in the body. The goal: more stable plasma concentrations, fewer side effects, lower dosing frequency and improved treatment adherence. Synonymous terms include modified release (MR), sustained release (SR), extended release (ER) and delayed release (DR) — each with a specific meaning in the pharmacopoeia.
Types of modified release formulations
Extended release (ER/SR)
The active substance is released over 8–24 hours. Peak plasma concentrations are reduced, troughs are raised — ideal for APIs with a narrow therapeutic index (carbamazepine, metformin, nifedipine). Mechanism: diffusion through a matrix polymer or membrane, erosion of a matrix, or osmotic drive.
Delayed release (DR)
Release is delayed until a specific location in the gastrointestinal tract — typically the small intestine or colon. Enteric coating is the best-known example: the coating dissolves at pH >5.5 (small intestine) and protects gastric-irritating APIs or acid-labile biologics.
Pulsatile release
Multiple release moments over time, triggered by colon bacteria (polysaccharide coatings), pH switches or pressure-sensitive systems. Application: chronopharmacology (antihypertensives for nocturnal blood pressure peaks).
Targeted release
Release at specific anatomical locations via ligand-receptor binding (nanoparticles with targeting ligands), mucoadhesion or local implants. Strongly growing segment driven by oncology and biologics.
Technology platforms for controlled release
Matrix tablets
The API is embedded in a polymer matrix (HPMC, ethylcellulose, Carbopol). Release via diffusion through the matrix and/or erosion of the polymer. Simple to produce via direct compression or granulation. Most widely used CR platform for oral solid dosage forms.
Reservoir systems
An API core surrounded by a rate-limiting membrane coating (ethylcellulose, Eudragit RS/RL). Release rate determined by membrane thickness and pore properties. Higher production precision required, but excellent release control.
Osmotic systems (OROS)
The OROS tablet (Alzet-type) uses osmotic pressure as the driving force: water penetrates through a semipermeable coating, builds up pressure and pushes the API out through a laser-drilled orifice. Release rate is near zero-order — virtually independent of GI motility and pH. High manufacturing precision required (laser orifice, coating thickness).
Lipid-based systems
Wax matrices (carnauba wax, beeswax, glyceryl behenate) for low-solubility APIs. Release via lipase-driven erosion. Applied to lipophilic APIs that are poorly soluble in aqueous media.
Regulatory aspects: IVIVC and bioequivalence
For modified release products, the FDA and EMA require an In Vitro-In Vivo Correlation (IVIVC) — a mathematical relationship between the in vitro release profile (dissolution) and in vivo pharmacokinetics. A level A IVIVC (point-to-point correlation) makes it possible to justify formulation changes without new clinical studies. Bioequivalence studies for CR products generally include tests in the fed and fasted state.
Manufacturing challenges
Controlled release places higher demands on process control than immediate release. Coating uniformity (standard deviation <3% weight gain per tablet), polymer concentration and drying conditions determine the release profile. Scale-up from lab to production is critical: fluid bed coaters and perforated pan coaters behave differently at large scale. Containment is an additional challenge for CR formulations of highly potent APIs — combining coating equipment with an isolator or RABS integration.
Conclusion
Controlled release technology is one of the most valuable tools in pharmaceutical formulation development: better therapeutic profile, higher patient compliance and extended product life cycle. The choice of the right platform depends on API properties, desired release profile, production capacity and regulatory strategy.
More about pharmaceutical manufacturing engineering: hecht-technology.nl.
Hecht Technology: particle size precision for modified release
Controlled release depends on a precisely defined particle size distribution of the API and excipients. Hecht Technology's Jett Mill enables reproducible, accurate particle size reduction — a critical process parameter in the development and manufacture of modified-release formulations.